Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 6/20 | 0.55 |
| ▸ | PTGES | O14684 | 6/20 | 0.53 |
| ▸ | NDUFS8 | O00217 | 1/20 | 0.53 |
| ▸ | COXFA4 | O00483 | 1/20 | 0.53 |
| ▸ | NDUFAB1 | O14561 | 1/20 | 0.53 |
| ▸ | NDUFA1 | O15239 | 1/20 | 0.53 |
| ▸ | NDUFS4 | O43181 | 1/20 | 0.53 |
| ▸ | NDUFB5 | O43674 | 1/20 | 0.53 |
| ▸ | NDUFB3 | O43676 | 1/20 | 0.53 |
| ▸ | NDUFC1 | O43677 | 1/20 | 0.53 |
| ▸ | NDUFA2 | O43678 | 1/20 | 0.53 |
| ▸ | NDUFS5 | O43920 | 1/20 | 0.53 |
| ▸ | NDUFS7 | O75251 | 1/20 | 0.53 |
| ▸ | NDUFS2 | O75306 | 1/20 | 0.53 |
| ▸ | NDUFS6 | O75380 | 1/20 | 0.53 |
| ▸ | NDUFB1 | O75438 | 1/20 | 0.53 |
| ▸ | NDUFS3 | O75489 | 1/20 | 0.53 |
| ▸ | NDUFB6 | O95139 | 1/20 | 0.53 |
| ▸ | NDUFA3 | O95167 | 1/20 | 0.53 |
| ▸ | NDUFB4 | O95168 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4556003 | 1.00 | ALOX15 (0.55) | ALOX15PTGESNDUFS8COXFA4NDUFAB1 | |
| SCHEMBL4437245 | 0.88 | TRPA1 (0.50) | ALOX15PTGESMTNR1AMAPT | |
| SCHEMBL8203204 | 0.84 | PTGES (0.59) | ALOX15PTGESNDUFS8COXFA4NDUFAB1 | |
| SCHEMBL8215581 | 0.82 | PTGES (0.60) | ALOX15PTGESNDUFS8COXFA4NDUFAB1 | |
| SCHEMBL31618356 | 0.80 | ALOX15 (0.55) | ALOX15PTGESNDUFS8COXFA4NDUFAB1 | |
| SCHEMBL10141846 | 0.80 | ALOX15 (0.55) | ALOX15PTGESNDUFS8COXFA4NDUFAB1 | |
| SCHEMBL24183222 | 0.79 | ALOX15 (0.61) | ALOX15PTGESNDUFS8COXFA4NDUFAB1 | |
| SCHEMBL6651834 | 0.77 | MTNR1A (0.53) | ALOX15PTGESNDUFS8COXFA4NDUFAB1 | |
| SCHEMBL6651830 | 0.77 | MTNR1A (0.53) | ALOX15PTGESNDUFS8COXFA4NDUFAB1 | |
| SCHEMBL11409991 | 0.76 | MAPT (0.56) | PTGESNDUFS8COXFA4NDUFAB1NDUFA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125825-A1 | ABCA1 ELEVATING COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080293757-A1 | ABCA1 ELEVATING COMPOUNDS | ABELMAN MATTHEW | 2008-11-27 | — | — | US | disclosed |
| US-20080293757-A1 | ABCA1 ELEVATING COMPOUNDS | ABELMAN MATTHEW | 2008-11-27 | — | — | US | disclosed |
| US-20080293757-A1 | ABCA1 ELEVATING COMPOUNDS | ABELMAN MATTHEW | 2008-11-27 | — | — | US | disclosed |
| US-7432276-B2 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432276-B2 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432276-B2 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7423045-B2 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423045-B2 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423045-B2 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. (US) | 2008-09-09 | — | — | US | disclosed |
| WO-2008079139-A1 | ABCA1 ELEVATING COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| EP-1907395-A1 | ABCA1 ELEVATING COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2008-04-09 | — | — | EP | disclosed |
| US-20070191379-A1 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070191379-A1 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070191379-A1 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070010544-A1 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. | 2007-01-11 | — | — | US | disclosed |
| US-20070010544-A1 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. | 2007-01-11 | — | — | US | disclosed |
| US-20070010544-A1 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. | 2007-01-11 | — | — | US | disclosed |
| WO-2007002867-A1 | ABCA1 ELEVATING COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002867-A1 | ABCA1 ELEVATING COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191379-A1 | ABCA1 elevating compounds | ABCD3, ABCB4, CETP | ALOX15 1300/4885PTGES 1136/4885NDUFS8 1132/4885 |
| US-20080293757-A1 | ABCA1 ELEVATING COMPOUNDS | ABCD3, ABCB4, CETP | ALOX15 1300/4885PTGES 1136/4885NDUFS8 1132/4885 |
| US-20070010544-A1 | ABCA1 elevating compounds | ABCD3, ABCB4, CETP | ALOX15 1300/4885PTGES 1136/4885NDUFS8 1132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.